Clinical Trials Sponsored by Eli+Lilly+and+Company

Total 2629 results

Eli Lilly and Company

Completed

Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma

Multiple Myeloma

Japan
Eli Lilly and Company

Completed

A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes

Diabetes Mellitus, Type 1

Denmark
Eli Lilly and Company

Completed

The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of LY2484595 on the Electrical Activity of the Heart

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of LY2928057 in Hemodialysis Participants

Renal Insufficiency, Chronic | Kidney Disease, Chronic

United States
Eli Lilly and Company

Completed

A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents

Colorectal Cancer | Mantle Cell Lymphoma | Advanced Cancer

United States, France, United Kingdom
Eli Lilly and Company

Completed

A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors

Solid Tumors

Japan
Eli Lilly and Company

Completed

A Study of LY2969822 in Healthy Participants

Healthy Volunteers

Singapore
Eli Lilly and Company

Completed

Single Dose Study in Healthy Participants to Investigate the Safety and Absorption of LY2584702

Healthy Participants

Singapore
Eli Lilly and Company

Completed

A Study of LY3113593 in Healthy Participants and Participants With Chronic Kidney Disease Treated With Hemodialysis

Kidney Failure, Chronic

United States
Eli Lilly and Company

Terminated

A Study of LY2584702 in Participants With Advanced Cancer

Advanced Cancer

United States
Eli Lilly and Company

Completed

A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States, Canada
Eli Lilly and Company

Completed

A Phase 1b Trial in Patients With Renal Cell Cancer

Metastatic Renal Cell Cancer

United States, Canada
Eli Lilly and Company

Completed

A Study of Ixekizumab in Participants With Active Psoriatic Arthritis (SPIRIT-P1)

Psoriasis, Arthritic

United States, Spain, Russian Federation, Belgium, Bulgaria, Canada, Czechia, Estonia, France, Japan, Mexico, Netherlands, Poland, Ukraine, United Kingdom
Eli Lilly and Company

Completed

A Study of LY2835219 in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of LY2835219 in Participants With Cancer

Neoplasm Metastasis | Neoplasm

United States
Eli Lilly and Company

Completed

A Study of Carbon-14-Labeled LY2835219 ([^14C]-LY2835219) in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart

Diabetes Mellitus, Type 2

United States
Eli Lilly and Company

Completed

A Study of Abemaciclib in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of Abemaciclib (LY2835219) in Healthy Participants With and Without Food

Healthy

United States
Eli Lilly and Company

Completed

A Study of LY3209590 in Participants With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Canada
Eli Lilly and Company

Completed

A Study of LY3375880 in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer

Carcinoma, Hepatocellular

Taiwan
Eli Lilly and Company

Completed

A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

United States, Spain, Taiwan, France, Japan, Mexico, Puerto Rico, Austria, Poland, Korea, Republic of, Argentina, Romania
Eli Lilly and Company

Completed

A Study of LY2608204 in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Singapore, United States
Eli Lilly and Company

Completed

A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics

Diabetes Mellitus, Type 2

United States
Eli Lilly and Company

Completed

A Study of LY2409021 in Participants With Different Levels of Kidney Function

Renal Insufficiency, Chronic | Kidney Failure, Chronic

Germany, United Kingdom
Eli Lilly and Company

Completed

A Study of LY2409021 in Healthy Participants

Healthy Participants

United States
Eli Lilly and Company

Completed

A Study of LY2216684 and Digoxin in Healthy Subjects

Major Depressive Disorder

United States
Eli Lilly and Company

Completed

A Study of Insulin Peglispro in Healthy Male Japanese Participants

Healthy Volunteers

Japan
Eli Lilly and Company

Completed

A Study of LY2605541 in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of LY2605541 in Healthy Participants and in the Elderly

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment

Hepatic Insufficiency

United States
Eli Lilly and Company

Completed

Study of Food on Evacetrapib (LY2484595) in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of Evacetrapib (LY2484595) in Participants With Severe Renal Impairment and in Healthy Participants

Cardiovascular Disease

United States
Eli Lilly and Company

Completed

A Study of LY2484595 in Healthy Subjects

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of Evacetrapib and Rifampin in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of Evacetrapib in Participants With Abnormal Cholesterol

Dyslipidemia

United States
Eli Lilly and Company

Completed

A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes

Diabetes Mellitus, Type 2

Singapore
Eli Lilly and Company

Completed

A Study of LY2584702 in Solid Tumors

Cancer

Japan
Eli Lilly and Company

Completed

A Study of Multiple Doses of LY3305677 in Healthy Participants

Healthy

United Kingdom
Eli Lilly and Company

Completed

A Single Dose Study of LY3023703 in Healthy Participants

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Dose-Escalation Study for Patients With Advanced Cancer

Advanced Cancer

United States
Eli Lilly and Company

Completed

A Study of LY2835219 in Healthy Participants

Healthy Volunteers

United Kingdom
Eli Lilly and Company

Completed

A Study of LY3084077 in Healthy Participants

Healthy Volunteers

Singapore
Eli Lilly and Company

Completed

A Study of Multiple Doses of LY2922470 in Participants With Diabetes

Diabetes Mellitus, Type 2

United States
Eli Lilly and Company

Completed

Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer

Adenocarcinoma of the Prostate

United States
Eli Lilly and Company

Completed

A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women

Healthy

United States
Eli Lilly and Company

Completed

A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy

Rheumatoid Arthritis

United States, Mexico, Hungary, India, Argentina, Chile, Ukraine, Australia, Romania, Germany, Poland, Slovakia
Eli Lilly and Company

Terminated

An Open Label Study for Participants With Rheumatoid Arthritis

Rheumatoid Arthritis

Argentina, Germany, India, Korea, Republic of, United States, Hungary, Taiwan, Bulgaria, France, Russian Federation, Spain, Ukraine, Colombia, Mexico, Poland, Japan, Croatia, Greece, New Zealand, Romania, South Africa, Australia, Br... and more

Clinical Trials Sponsored by Eli+Lilly+and+Company

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations